On Sept. 22, The Pink Sheet, a medical trade publication, reported the FDA had said that Pfizer received an "approvable letter" from the FDA. Such letters are not approvals but instead a kind of delay, saying that most of the data needed for approval are in but that additional steps need to be taken if the drug is to reach the market.
FORBES: Pfizer Plays A Guessing Game